Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial

Beier, Jutta; Chanez, Pascal; Martinot, Jean-Benoît; Schreurs, A. J. M.; Tkácová, R; Bao, Weibin; Jack, Damon; Higgins, Mark

doi:10.1016/j.pupt.2006.09.001

Cited by 79 publications

(56 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have demonstrated the 24-h bronchodilator efficacy of indacaterol in subjects with COPD 7,8 ; this is the first comparison with formoterol. In addition to the potential advantages of greater convenience for the patient of once-daily versus twice-daily dosing, the superior bronchodilator efficacy at time points when formoterol's effect is tailing off may be reflected in a smoother and more sustained control of symptoms and, importantly, peripheral lung emptying under resting conditions, which may be reflected by the superior effect of indacaterol on trough IC at 24 h post-dose.…”

Section: Discussionmentioning

confidence: 75%

“…Indacaterol is a novel inhaled ultra-long-acting β 2 -agonist (ultra-LABA) being investigated for once-daily use in subjects with COPD 7,8 . Improved clinical benefits have been demonstrated with the long-acting anticholinergic tiotropium once-daily versus short-acting ipratropium four-times daily 9 , and one of the proposed underlying mechanisms for this observation may be a prolonged effect of long-acting bronchodilators on lung emptying, by improving IC and reducing resting hyperinflation.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Bronchodilator effects of indacaterol and formoterol in patients with COPD

Beier

Beeh

Brookman

et al. 2009

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

Bronchodilator effects of indacaterol and formoterol in patients with COPD

Beier

Beeh

Brookman

et al. 2009

Pulmonary Pharmacology & Therapeutics

View full text Add to dashboard Cite

show abstract

“…In pre-clinical studies in guinea pigs, indacaterol demonstrated a longer duration of action and faster onset than salmeterol [14]. Clinical studies have indicated that indacaterol might be used as a once-daily compound [15], which would be of great interest regarding patient convenience and compliance with treatment.…”

mentioning

confidence: 99%

Effect of indacaterol, a novel long-acting β₂-agonist, on isolated human bronchi

Naline¹,

Trifilieff²,

Fairhurst³

et al. 2006

Eur Respir J

101

View full text Add to dashboard Cite

Indacaterol is a novel b 2 -adrenoceptor agonist in development for the once-daily treatment of asthma and chronic obstructive pulmonary disease. The present study evaluated the relaxant effect of indacaterol on isolated human bronchi obtained from lungs of patients undergoing surgery for lung carcinoma.Potency (-logEC50), maximal relaxant effect (Emax) and onset of action were determined at resting tone. Duration of action was determined against cholinergic neural contraction induced by electrical field stimulation (EFS).At resting tone, -logEC50 and Emax values were 8.82¡0.41 and 77¡5% for indacaterol, 9.84¡0.22 and 94¡1% for formoterol, 8.36¡0.16 and 74¡4% for salmeterol, and 8.43¡0.22 and 84¡4% for salbutamol, respectively.In contrast to salmeterol, indacaterol did not antagonise the isoprenaline response. Indacaterol's onset of action (7.8¡0.7 min) was not significantly different from that of formoterol (5.8¡0.7 min) or salbutamol (11.0¡4.0 min), but it was significantly faster than that of salmeterol (19.4¡4.3 min). EFS-induced contractions were inhibited with -logIC50 values of 6.96¡0.13 (indacaterol), 8.96¡0.18 (formoterol), 7.18¡0.34 (salmeterol) and 6.39¡0.26 (salbutamol). Duration of action was .12 h for indacaterol and salmeterol, and 35.3¡8.8 and 14.6¡3.7 min for formoterol and salbutamol, respectively.In isolated human bronchi, indacaterol behaved as a long-acting b 2 -adrenoceptor agonist with high intrinsic efficacy and fast onset of action.

show abstract

“…Both doses of indacaterol demonstrated a good overall safety profile, with no clinically relevant differences between treatment groups in any of the cardiovascular or biochemical variables assessed [Beier et al 2007]. …”

Section: Safety Issuesmentioning

confidence: 99%

Indacaterol in chronic obstructive pulmonary disease: an update for clinicians

Yorgancıoğlu¹

2011

Therapeutic Advances in Chronic Disease

View full text Add to dashboard Cite

Bronchodilation is the cornerstone of chronic obstructive pulmonary disease (COPD) management and is based on regular treatment with one or more long-acting b 2 agonists (LABAs). A novel bronchodilator, indacaterol, satisfies the requirements of an efficacious LABA: it has a relatively longer duration of action compared with existing LABAs and a fast onset of action. This review is a presentation of data on indacaterol with respect to its molecular characteristics as well as comparisons with other long-acting bronchodilators. Data from 12 relevant trials show that once-daily indacaterol provides significant, consistent and clinically important improvements in lung function (forced expiratory volume in 1 second), significant improvements in breathlessness and health status at least as good as or better than tiotropium, salmeterol and formoterol, and reduction in requirement for relief medication compared with tiotropium, salmeterol and formoterol.

show abstract

Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial

Cited by 79 publications

References 19 publications

Bronchodilator effects of indacaterol and formoterol in patients with COPD

Bronchodilator effects of indacaterol and formoterol in patients with COPD

Effect of indacaterol, a novel long-acting β₂-agonist, on isolated human bronchi

Indacaterol in chronic obstructive pulmonary disease: an update for clinicians

Contact Info

Product

Resources

About

Safety, tolerability and efficacy of indacaterol, a novel once-daily β2-agonist, in patients with COPD: A 28-day randomised, placebo controlled clinical trial

Cited by 79 publications

References 19 publications

Bronchodilator effects of indacaterol and formoterol in patients with COPD

Bronchodilator effects of indacaterol and formoterol in patients with COPD

Effect of indacaterol, a novel long-acting β2-agonist, on isolated human bronchi

Indacaterol in chronic obstructive pulmonary disease: an update for clinicians

Contact Info

Product

Resources

About

Effect of indacaterol, a novel long-acting β₂-agonist, on isolated human bronchi